OPKO Health Valuation
Is OPK * undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
3/6Valuation Score 3/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of OPK * when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: OPK * (MX$21.5) is trading below our estimate of fair value (MX$81.41)
Significantly Below Fair Value: OPK * is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for OPK *?
Other financial metrics that can be useful for relative valuation.
What is OPK *'s n/a Ratio? | |
---|---|
n/a | 0x |
n/a | n/a |
Market Cap | US$850.33m |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 1.3x |
Enterprise Value/EBITDA | -20.5x |
PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does OPK *'s PS Ratio compare to its peers?
Company | Forward PS | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 2.3x | ||
MEDICA B Médica Sur. de | 1.1x | 5.2% | Mex$4.4b |
FLGT Fulgent Genetics | 2.1x | 7.0% | US$608.5m |
4544 H.U. Group Holdings | 0.5x | 2.5% | JP¥129.7b |
NRC National Research | 5.6x | n/a | US$817.4m |
OPK * OPKO Health | 1x | 5.0% | Mex$850.3m |
Price-To-Sales vs Peers: OPK * is good value based on its Price-To-Sales Ratio (1x) compared to the peer average (2.3x).
Price to Earnings Ratio vs Industry
How does OPK *'s PE Ratio compare vs other companies in the South American Healthcare Industry?
Price-To-Sales vs Industry: OPK * is expensive based on its Price-To-Sales Ratio (1x) compared to the South American Healthcare industry average (0.9x).
Price to Sales Ratio vs Fair Ratio
What is OPK *'s PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PS Ratio | 1x |
Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate OPK *'s Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
---|---|---|---|---|---|---|---|
Current | n/a | Mex$72.56 0% | 53.8% | Mex$145.13 | Mex$25.61 | n/a | 6 |
Apr ’25 | n/a | Mex$72.67 0% | 53.8% | Mex$145.33 | Mex$25.65 | n/a | 6 |
Mar ’25 | Mex$17.00 | Mex$72.67 +327.5% | 53.8% | Mex$145.33 | Mex$25.65 | n/a | 6 |
Feb ’25 | n/a | Mex$73.13 0% | 50.6% | Mex$143.44 | Mex$33.75 | n/a | 6 |
Jan ’25 | n/a | Mex$77.28 0% | 48.2% | Mex$148.73 | Mex$35.00 | n/a | 6 |
Dec ’24 | Mex$25.33 | Mex$77.28 +205.1% | 48.2% | Mex$148.73 | Mex$35.00 | n/a | 6 |
Nov ’24 | n/a | Mex$76.64 0% | 48.0% | Mex$145.31 | Mex$34.19 | n/a | 6 |
Oct ’24 | n/a | Mex$76.64 0% | 48.0% | Mex$145.31 | Mex$34.19 | n/a | 6 |
Sep ’24 | n/a | Mex$76.64 0% | 48.0% | Mex$145.31 | Mex$34.19 | n/a | 6 |
Aug ’24 | Mex$30.00 | Mex$73.87 +146.2% | 49.7% | Mex$145.45 | Mex$34.22 | n/a | 6 |
Jul ’24 | Mex$30.00 | Mex$73.87 +146.2% | 49.7% | Mex$145.45 | Mex$34.22 | n/a | 6 |
Jun ’24 | n/a | Mex$84.99 0% | 43.0% | Mex$151.12 | Mex$53.34 | n/a | 5 |
May ’24 | n/a | Mex$88.89 0% | 43.0% | Mex$155.78 | Mex$54.98 | n/a | 5 |
Apr ’24 | Mex$25.00 | Mex$88.89 +255.6% | 43.0% | Mex$155.78 | Mex$54.98 | n/a | 5 |
Mar ’24 | Mex$22.00 | Mex$88.75 +303.4% | 43.0% | Mex$155.54 | Mex$54.90 | Mex$17.00 | 5 |
Feb ’24 | n/a | Mex$97.80 0% | 40.5% | Mex$167.93 | Mex$59.27 | n/a | 5 |
Jan ’24 | n/a | Mex$97.80 0% | 40.5% | Mex$167.93 | Mex$59.27 | n/a | 5 |
Dec ’23 | n/a | Mex$106.48 0% | 36.0% | Mex$166.45 | Mex$68.54 | Mex$25.33 | 4 |
Nov ’23 | n/a | Mex$115.20 0% | 30.7% | Mex$172.16 | Mex$81.02 | n/a | 4 |
Oct ’23 | n/a | Mex$115.20 0% | 30.7% | Mex$172.16 | Mex$81.02 | n/a | 4 |
Sep ’23 | n/a | Mex$115.20 0% | 30.7% | Mex$172.16 | Mex$81.02 | n/a | 4 |
Aug ’23 | Mex$50.00 | Mex$132.46 +164.9% | 23.7% | Mex$173.21 | Mex$101.89 | Mex$30.00 | 4 |
Jul ’23 | Mex$52.00 | Mex$132.46 +154.7% | 23.7% | Mex$173.21 | Mex$101.89 | Mex$30.00 | 4 |
Jun ’23 | Mex$60.00 | Mex$132.46 +120.8% | 23.7% | Mex$173.21 | Mex$101.89 | n/a | 4 |
May ’23 | Mex$56.80 | Mex$137.49 +142.1% | 17.3% | Mex$169.99 | Mex$110.00 | n/a | 4 |
Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.